Key changes to revised formulary section - eye

Section 2 Cardiovascular
June 2010
Vasodilator antihypertensive drugs - minoxidil, sodium nitroprusside.
Centrally acting - clonidine
Calcium Channel Blockers - Dihydropyridines - nifedipine
Inotropic Sympathomimetics - dopexamine
Oral anticoagulants - phenindione
Antifibrinolytics - etamsylate
Bile acid sequestrants - colestipol
Dabigatran etexilate (Pradaxa®). Restricted use for the prevention of stroke and
systemic embolism in adult patients with non-valvular atrial fibrillation with one or
more risk factors. Restricted to patients in whom there is poor INR control with
warfarin unrelated to compliance or in patients who are genuinely intolerant of
Section 3 Respiratory
June 2011
SABA choice - terbutaline removed. LABAs - Indacaterol moved to restricted list. Cromoglicate and related therapy - no products recommended. Sodium cromoglicate, nedocromil sodium removed. Leukotriene receptor antagonists - zafirlukast removed. Allergen immunotherapy - Omalizumab moved to restricted list. Respiratory stimulants and pulmonary surfactants moved to the restricted list. Section 4 CNS
February 2010
Sibutramine for treatment of obesity. Marketing authorisation suspended due to risk of cardiovascular adverse effects. Instanyl® nasal spray. Preferred nasal spray formulation is PecFent® Section 5 Infections
June 2010
Antipseudomonal penicillins -Tazocin® (replaced with generic name).
Cephalosporins - Cefaclor and cefuroxime for general use in primary care.
Tetracyclines - Minocycline.
Aminoglycosides - Neomycin
Anti-tuberculous drugs -
Quinolones - Moxifloxacin
Antifungal drugs - Flucytosine
HIV Infection - Combivir®
Statement stating Famciclovir is not approved for genital herpes. CMV Infection - Foscarnet
- Amantadine
RSV - Ribavarin
Antimalarials - Primaquine
Pneumocystis Pneumonia - Pentamidine
Enfuviritide. In combination with other anti-retroviral medicinal products for the
treatment of human immunodeficiency virus (HIV-1) infection in adult patients.
Section 6 Endocrine System
April 2010
Vildagliptin (Galvus®). Treatment of type 2 diabetes mellitus in combination with metformin. Replaced by saxagliptin. Rosiglitazone (Avandia®, Avandamet®). Treatment of type 2 diabetes mellitus. Marketing authorisation suspended due to risk of cardiovascular adverse effects. Section 7 Obstetrics, gynaecology and urinary tract disorders
December 2010
Implanon® Contraceptive Implant. Replaced by Nexplanon®. Section 9 Nutrition and Blood
October 2011
Calcichew-D3®, Calfovit®, Calceos® Calcium and vitamin D preparations. Formulary choice for all formulations is Adcal-D3 range. Section 10 Musculoskeletal
October 2011
Coxibs - no longer recommended as formulary choices for any group of patients. Only to be used when at least 2 standard NSAIDs have been ineffective / not tolerated. Topicasl NSAIDs - ketoprofen, Algesal, Movelat, Transvasin. Section 11 Eye
October 2009
Removal of non-specific second line agents i.e. gentamicin, polyfax, propamidine Corticosteroids - Removed statement about prescribing in primary care on acute prescription only and reviewing every 2 months. Mydriatics - Removed homatropine as antimuscarinic choice Beta-blockers - removed carteolol, levobunolol Peri-operative preps. - Removal of flurbiprofen, acetylcholine chloride, apraclonidine. AMD - Removal of pegaptinib Section 12 ENT
March 2012
Fluticasone propionate nasal spray. Triamcinolone nasal spray Azelastine nasal spray Budesonide nasal spray Adcortyl in Orabase Amphoteracin lozenges Section 13 Skin
December 2009
Medium weight emollients - Calmurid, Hydromol cream, Unguentum M Bath additives - Aveeno, Hydromol. Barrier preps. - Epaderm Rosacea Oral choices - Lymecycline, minocycline Camouflagers - Covermark Cocois scalp ointment


Microsoft word - guardian complete worming chews.doc

Product Name: Guardian Complete Worming Chews This revision issued: August, 2011 Page: 1 of 5 Section 1 - Identification of The Material and Supplier Issued by: Intervet Australia Pty Limited (known as MSD Animal Health) 91-105 Harpin Street Tel: 1 800 033 461 (Business hours) Bendigo East, Vic 3550, AUSTRALIA Fax: 1 800 817 414 Company ABN: 79 008 467

Beter effect antidepressiva — pw | pharmaceutisch weekblad

Beter effect antidepressiva Suppletie foliumzuur bij gebruik fluoxetine door Ary van der Kuy, Lan Kiauw de Munck-Khoe - 05-10-2012 Foliumzuur verbetert vaak de respons op fluoxetine en andere antidepressiva bij therapieresistente patiënten. Foliumzuur is nodig voor de synthese van monoamine-neurotransmitters. • Casus Een 54-jarige man met de diagnose ernstige depressie, zonder p

Copyright © 2018 Predicting Disease Pdf